...
首页> 外文期刊>Journal of the Egyptian Women s Dermatologic Society >Immunohistochemical expression of CD117 and CD34 as stem cell markers in intradermal nevi, dysplastic nevi, and malignant melanomas
【24h】

Immunohistochemical expression of CD117 and CD34 as stem cell markers in intradermal nevi, dysplastic nevi, and malignant melanomas

机译:CD117和CD34作为干细胞标志物在皮内痣,发育不良痣和恶性黑色素瘤中的免疫组织化学表达

获取原文
           

摘要

eradicate cancer stem cells might have significant clinical implications. Objective The aim of this study was to assess the immunohistochemical expression of both CD117 and CD34 as stem cell markers in intradermal nevi, dysplastic nevi, and malignant melanoma (MM). Patients and methods The present study included a total of 38 patients; 11 patients with intradermal nevi, nine patients with dysplastic nevi, and 18 patients with MM (12 primary, four metastatic, and two recurrent). Using immunohistochemistry, we studied CD117 and CD34 in the tissue of all studied patients. Results Intradermal nevi were all negative for CD117, whereas dysplastic nevi showed 100% positivity and MMs showed 83.3% positivity. There was statistically significant difference between intradermal nevi and both dysplastic nevi and MMs, but no significant difference was found between the last two in CD117 expression. Intradermal nevi were completely negative for CD34 expression, the dysplastic nevi showed positivity in 6/9 (66.7%) patients and MM showed expression in 2/18 (11%). There was a statistically significant difference between intradermal nevi and both dysplastic nevi and MMs and between the last two in terms of CD34 expression. Conclusion CD117 could be considered as an indicator of malignant proliferative process. It could further be a useful marker to differentiate completely benign nevi from malignant melanocytic lesions. This may have therapeutic implications as a molecular target, which needs further investigations. CD34 neither has a role as a stem cell marker nor is a potential target for clinical trials with monoclonal antibody therapy in MMs....
机译:根除癌症干细胞可能具有重要的临床意义。目的本研究的目的是评估CD117和CD34作为干细胞标志物在真皮内痣,增生性痣和恶性黑色素瘤(MM)中的免疫组织化学表达。患者和方法本研究共纳入38例患者,其中包括2例患者。皮内痣11例,增生痣9例,MM 18例(原发性12例,转移性4例,复发2例)。使用免疫组织化学,我们研究了所有研究患者组织中的CD117和CD34。结果皮内痣均为CD117阴性,增生痣阳性率为100%,MMs阳性率为83.3%。皮内痣与增生性痣和MMs之间在统计学上有显着差异,但最后两个CD117表达之间没有发现显着差异。皮内痣对CD34表达完全阴性,增生痣在6/9(66.7%)患者中呈阳性,而MM在2/18(11%)中表达。就CD34表达而言,真皮内痣与增生性痣和MM以及后两者之间在统计学上有显着差异。结论CD117可作为恶性增生过程的指标。它可能进一步成为区分恶性黑色素细胞病变完全良性痣的有用标志物。这可能作为分子靶标具有治疗意义,需要进一步研究。 CD34既不充当干细胞标志物,也不是针对MMs进行单克隆抗体治疗的临床试验的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号